Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-09-15

AUTHORS

Elizabeth L. Berg, Stela P. Petkova, Heather A. Born, Anna Adhikari, Anne E. Anderson, Jill L. Silverman

ABSTRACT

BackgroundAngelman Syndrome (AS) is a rare neurodevelopmental disorder for which there is currently no cure or effective therapeutic. Since the genetic cause of AS is known to be dysfunctional expression of the maternal allele of ubiquitin protein ligase E3A (UBE3A), several genetic animal models of AS have been developed. Both the Ube3a maternal deletion mouse and rat models of AS reliably demonstrate behavioral phenotypes of relevance to AS and therefore offer suitable in vivo systems in which to test potential therapeutics. One promising candidate treatment is insulin-like growth factor-2 (IGF-2), which has recently been shown to ameliorate behavioral deficits in the mouse model of AS and improve cognitive abilities across model systems.MethodsWe used both the Ube3a maternal deletion mouse and rat models of AS to evaluate the ability of IGF-2 to improve electrophysiological and behavioral outcomes.ResultsAcute systemic administration of IGF-2 had an effect on electrophysiological activity in the brain and on a metric of motor ability; however the effects were not enduring or extensive. Additional metrics of motor behavior, learning, ambulation, and coordination were unaffected and IGF-2 did not improve social communication, seizure threshold, or cognition.LimitationsThe generalizability of these results to humans is difficult to predict and it remains possible that dosing schemes (i.e., chronic or subchronic dosing), routes, and/or post-treatment intervals other than that used herein may show more efficacy.ConclusionsDespite a few observed effects of IGF-2, our results taken together indicate that IGF-2 treatment does not profoundly improve behavioral deficits in mouse or rat models of AS. These findings shed cautionary light on the potential utility of acute systemic IGF-2 administration in the treatment of AS. More... »

PAGES

59

References to SciGraph publications

  • 2020-01-27. Translational outcomes in a full gene deletion of ubiquitin protein ligase E3A rat model of Angelman syndrome in TRANSLATIONAL PSYCHIATRY
  • 1997-09. Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons in NATURE GENETICS
  • 2013-06-11. SHANK3 haploinsufficiency: a “common” but underdiagnosed highly penetrant monogenic cause of autism spectrum disorders in MOLECULAR AUTISM
  • 2015-11-18. Acoustic Communication in Rats: Effects of Social Experiences on Ultrasonic Vocalizations as Socio-affective Signals in SOCIAL BEHAVIOR FROM RODENTS TO HUMANS
  • 2014-03-19. Enhancement of Memories by Systemic Administration of Insulin-Like Growth Factor II in NEUROPSYCHOPHARMACOLOGY
  • 2006-12-17. Mutations in the gene encoding the synaptic scaffolding protein SHANK3 are associated with autism spectrum disorders in NATURE GENETICS
  • 2018-09-14. A behavioral test battery for mouse models of Angelman syndrome: a powerful tool for testing drugs and novel Ube3a mutants in MOLECULAR AUTISM
  • 2014-12-12. A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome in MOLECULAR AUTISM
  • 1997-01. UBE3A/E6-AP mutations cause Angelman syndrome in NATURE GENETICS
  • 1997-01. De novo truncating mutations in E6-AP ubiquitin-protein ligase gene (UBE3A) in Angelman syndrome in NATURE GENETICS
  • 2020-08-17. Developmental exposure to near roadway pollution produces behavioral phenotypes relevant to neurodevelopmental disorders in juvenile rats in TRANSLATIONAL PSYCHIATRY
  • 2021-02-06. Abnormal electrophysiological phenotypes and sleep deficits in a mouse model of Angelman Syndrome in MOLECULAR AUTISM
  • 2013-04-27. Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay in MOLECULAR AUTISM
  • 2009-05-10. Ube3a is required for experience-dependent maturation of the neocortex in NATURE NEUROSCIENCE
  • 2016-09-12. Angelman syndrome — insights into a rare neurogenetic disorder in NATURE REVIEWS NEUROLOGY
  • 2014-08-22. Righting Rett syndrome with IGF1 in NATURE REVIEWS DRUG DISCOVERY
  • 2006-08. Object recognition in rats and mice: a one-trial non-matching-to-sample learning task to study 'recognition memory' in NATURE PROTOCOLS
  • 2015-06-02. Erratum: A pilot controlled trial of insulin-like growth factor-1 in children with Phelan-McDermid syndrome in MOLECULAR AUTISM
  • 2018-04-27. Abnormal coherence and sleep composition in children with Angelman syndrome: a retrospective EEG study in MOLECULAR AUTISM
  • 2020-12-16. Translational outcomes relevant to neurodevelopmental disorders following early life exposure of rats to chlorpyrifos in JOURNAL OF NEURODEVELOPMENTAL DISORDERS
  • 2015-03-10. GABAB Receptor Agonist R-Baclofen Reverses Social Deficits and Reduces Repetitive Behavior in Two Mouse Models of Autism in NEUROPSYCHOPHARMACOLOGY
  • 2017-06-15. Replicable in vivo physiological and behavioral phenotypes of the Shank3B null mutant mouse model of autism in MOLECULAR AUTISM
  • 2020-06-26. IGF-1 treatment causes unique transcriptional response in neurons from individuals with idiopathic autism in MOLECULAR AUTISM
  • 2010-07. Behavioural phenotyping assays for mouse models of autism in NATURE REVIEWS NEUROSCIENCE
  • 2017-08-16. Strain-dependence of the Angelman Syndrome phenotypes in Ube3a maternal deficiency mice in SCIENTIFIC REPORTS
  • 2014-06-04. Clinical utility gene card for: Angelman Syndrome in EUROPEAN JOURNAL OF HUMAN GENETICS
  • 2021-03-23. Neuroanatomy and behavior in mice with a haploinsufficiency of AT-rich interactive domain 1B (ARID1B) throughout development in MOLECULAR AUTISM
  • 2017-05-08. Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis in JOURNAL OF NEURODEVELOPMENTAL DISORDERS
  • 2017-06-26. Germline Chd8 haploinsufficiency alters brain development in mouse in NATURE NEUROSCIENCE
  • 2017-07-17. Erratum to: Delta rhythmicity is a reliable EEG biomarker in Angelman syndrome: a parallel mouse and human analysis in JOURNAL OF NEURODEVELOPMENTAL DISORDERS
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s13229-021-00467-1

    DOI

    http://dx.doi.org/10.1186/s13229-021-00467-1

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1141139387

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/34526125


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Clinical Sciences", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Alleles", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Angelman Syndrome", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Animals", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Brain", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Disease Models, Animal", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Insulin-Like Growth Factor II", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Mice", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Rats", 
            "type": "DefinedTerm"
          }, 
          {
            "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
            "name": "Ubiquitin-Protein Ligases", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.27860.3b", 
              "name": [
                "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Berg", 
            "givenName": "Elizabeth L.", 
            "id": "sg:person.012023440035.42", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012023440035.42"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.27860.3b", 
              "name": [
                "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Petkova", 
            "givenName": "Stela P.", 
            "id": "sg:person.011662573367.49", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011662573367.49"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA", 
              "id": "http://www.grid.ac/institutes/grid.25879.31", 
              "name": [
                "Department of Pediatrics and Neurology, Baylor College of Medicine, Houston, TX, USA", 
                "Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Born", 
            "givenName": "Heather A.", 
            "id": "sg:person.01020406761.29", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020406761.29"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.27860.3b", 
              "name": [
                "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Adhikari", 
            "givenName": "Anna", 
            "id": "sg:person.012750173376.16", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012750173376.16"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Department of Pediatrics and Neurology, Baylor College of Medicine, Houston, TX, USA", 
              "id": "http://www.grid.ac/institutes/grid.39382.33", 
              "name": [
                "Department of Pediatrics and Neurology, Baylor College of Medicine, Houston, TX, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Anderson", 
            "givenName": "Anne E.", 
            "id": "sg:person.01122163343.90", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122163343.90"
            ], 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA", 
              "id": "http://www.grid.ac/institutes/grid.27860.3b", 
              "name": [
                "MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Silverman", 
            "givenName": "Jill L.", 
            "id": "sg:person.01314575247.20", 
            "sameAs": [
              "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314575247.20"
            ], 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "sg:pub.10.1038/nrn2851", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1027382882", 
              "https://doi.org/10.1038/nrn2851"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13229-021-00416-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1135183861", 
              "https://doi.org/10.1186/s13229-021-00416-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13229-020-00359-w", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1128794428", 
              "https://doi.org/10.1186/s13229-020-00359-w"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0997-75", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1021073892", 
              "https://doi.org/10.1038/ng0997-75"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ejhg.2014.93", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1026331838", 
              "https://doi.org/10.1038/ejhg.2014.93"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41398-020-0720-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1124912055", 
              "https://doi.org/10.1038/s41398-020-0720-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s11689-017-9210-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1090740834", 
              "https://doi.org/10.1186/s11689-017-9210-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/7854_2015_410", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1003623049", 
              "https://doi.org/10.1007/7854_2015_410"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nn.4592", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1086240047", 
              "https://doi.org/10.1038/nn.4592"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13229-018-0214-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103669008", 
              "https://doi.org/10.1186/s13229-018-0214-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2040-2392-5-54", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040138850", 
              "https://doi.org/10.1186/2040-2392-5-54"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13229-017-0142-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1086046227", 
              "https://doi.org/10.1186/s13229-017-0142-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41398-020-00978-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1130147581", 
              "https://doi.org/10.1038/s41398-020-00978-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/npp.2014.69", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004023865", 
              "https://doi.org/10.1038/npp.2014.69"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/npp.2015.66", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004112236", 
              "https://doi.org/10.1038/npp.2015.66"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0197-74", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1015416100", 
              "https://doi.org/10.1038/ng0197-74"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2040-2392-4-9", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018240013", 
              "https://doi.org/10.1186/2040-2392-4-9"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrneurol.2016.133", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1017529529", 
              "https://doi.org/10.1038/nrneurol.2016.133"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13229-021-00432-y", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1136612444", 
              "https://doi.org/10.1186/s13229-021-00432-y"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s11689-017-9195-8", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1085208297", 
              "https://doi.org/10.1186/s11689-017-9195-8"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/2040-2392-4-17", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030578974", 
              "https://doi.org/10.1186/2040-2392-4-17"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s11689-020-09342-1", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1133569238", 
              "https://doi.org/10.1186/s11689-020-09342-1"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13229-015-0025-0", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022525805", 
              "https://doi.org/10.1186/s13229-015-0025-0"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/s41598-017-08825-x", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091148379", 
              "https://doi.org/10.1038/s41598-017-08825-x"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nprot.2006.205", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1031855645", 
              "https://doi.org/10.1038/nprot.2006.205"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/s13229-018-0231-7", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1106989860", 
              "https://doi.org/10.1186/s13229-018-0231-7"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrd4417", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006881263", 
              "https://doi.org/10.1038/nrd4417"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nn.2327", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033476316", 
              "https://doi.org/10.1038/nn.2327"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng0197-70", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012945311", 
              "https://doi.org/10.1038/ng0197-70"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/ng1933", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006673623", 
              "https://doi.org/10.1038/ng1933"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2021-09-15", 
        "datePublishedReg": "2021-09-15", 
        "description": "BackgroundAngelman Syndrome (AS) is a rare neurodevelopmental disorder for which there is currently no cure or effective therapeutic. Since the genetic cause of AS is known to be dysfunctional expression of the maternal allele of ubiquitin protein ligase E3A (UBE3A), several genetic animal models of AS have been developed. Both the Ube3a maternal deletion mouse and rat models of AS reliably demonstrate behavioral phenotypes of relevance to AS and therefore offer suitable in vivo systems in which to test potential therapeutics. One promising candidate treatment is insulin-like growth factor-2 (IGF-2), which has recently been shown to ameliorate behavioral deficits in the mouse model of AS and improve cognitive abilities across model systems.MethodsWe used both the Ube3a maternal deletion mouse and rat models of AS to evaluate the ability of IGF-2 to improve electrophysiological and behavioral outcomes.ResultsAcute systemic administration of IGF-2 had an effect on electrophysiological activity in the brain and on a metric of motor ability; however the effects were not enduring or extensive. Additional metrics of motor behavior, learning, ambulation, and coordination were unaffected and IGF-2 did not improve social communication, seizure threshold, or cognition.LimitationsThe generalizability of these results to humans is difficult to predict and it remains possible that dosing schemes (i.e., chronic or subchronic dosing), routes, and/or post-treatment intervals other than that used herein may show more efficacy.ConclusionsDespite a few observed effects of IGF-2, our results taken together indicate that IGF-2 treatment does not profoundly improve behavioral deficits in mouse or rat models of AS. These findings shed cautionary light on the potential utility of acute systemic IGF-2 administration in the treatment of AS.", 
        "genre": "article", 
        "id": "sg:pub.10.1186/s13229-021-00467-1", 
        "inLanguage": "en", 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2699307", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.6664430", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1043709", 
            "issn": [
              "2040-2392"
            ], 
            "name": "Molecular Autism", 
            "publisher": "Springer Nature", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "12"
          }
        ], 
        "keywords": [
          "insulin-like growth factor 2", 
          "rat model", 
          "behavioral deficits", 
          "growth factor 2", 
          "deletion mice", 
          "promising candidate treatment", 
          "ameliorate behavioral deficits", 
          "treatment of AS", 
          "rare neurodevelopmental disorder", 
          "ubiquitin protein ligase E3A", 
          "genetic animal models", 
          "factor 2", 
          "post-treatment intervals", 
          "seizure threshold", 
          "systemic administration", 
          "mouse model", 
          "candidate treatment", 
          "animal models", 
          "effective therapeutics", 
          "motor behavior", 
          "mice", 
          "more efficacy", 
          "genetic cause", 
          "potential therapeutics", 
          "neurodevelopmental disorders", 
          "motor abilities", 
          "electrophysiological activity", 
          "dysfunctional expression", 
          "Angelman syndrome", 
          "syndrome", 
          "treatment", 
          "behavioral phenotypes", 
          "administration", 
          "vivo system", 
          "behavioral outcomes", 
          "deficits", 
          "potential utility", 
          "therapeutics", 
          "maternal allele", 
          "ambulation", 
          "MethodsWe", 
          "cautionary light", 
          "AS", 
          "brain", 
          "disorders", 
          "efficacy", 
          "observed effects", 
          "cure", 
          "outcomes", 
          "effect", 
          "cause", 
          "cognitive abilities", 
          "phenotype", 
          "humans", 
          "expression", 
          "ability", 
          "findings", 
          "E3A", 
          "alleles", 
          "interval", 
          "activity", 
          "social communication", 
          "model system", 
          "generalizability", 
          "cognition", 
          "relevance", 
          "utility", 
          "results", 
          "threshold", 
          "model", 
          "additional metrics", 
          "route", 
          "system", 
          "coordination", 
          "communication", 
          "light", 
          "behavior", 
          "metrics", 
          "learning", 
          "scheme"
        ], 
        "name": "Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome", 
        "pagination": "59", 
        "productId": [
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1141139387"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s13229-021-00467-1"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "34526125"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s13229-021-00467-1", 
          "https://app.dimensions.ai/details/publication/pub.1141139387"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2022-05-10T10:30", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-springernature-scigraph/baseset/20220509/entities/gbq_results/article/article_881.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://doi.org/10.1186/s13229-021-00467-1"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13229-021-00467-1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13229-021-00467-1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13229-021-00467-1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13229-021-00467-1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    343 TRIPLES      22 PREDICATES      145 URIs      107 LITERALS      16 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s13229-021-00467-1 schema:about N116e2863e9ac4affa16f9c0e4ccfd134
    2 N23819f1ff8a244fb8d87af0a26be696b
    3 N43495c2784c441dfb4d911afc1228f9f
    4 N49d2e3f3e4444d3689754c34e4deca13
    5 N4b3b2bdda51941d48d218f3b43ba803c
    6 N5130de51710b430aa09e4a60e752d9d2
    7 N515ab317165940f9b00ab96a62002b76
    8 Nc4af4a7bc7be4bd1bb8e5750253d1a05
    9 Nd30ae584d3fd4d81b0c474a5d375ab06
    10 anzsrc-for:11
    11 anzsrc-for:1103
    12 schema:author N7f891e4371844b90b64f8822e56e72f1
    13 schema:citation sg:pub.10.1007/7854_2015_410
    14 sg:pub.10.1038/ejhg.2014.93
    15 sg:pub.10.1038/ng0197-70
    16 sg:pub.10.1038/ng0197-74
    17 sg:pub.10.1038/ng0997-75
    18 sg:pub.10.1038/ng1933
    19 sg:pub.10.1038/nn.2327
    20 sg:pub.10.1038/nn.4592
    21 sg:pub.10.1038/npp.2014.69
    22 sg:pub.10.1038/npp.2015.66
    23 sg:pub.10.1038/nprot.2006.205
    24 sg:pub.10.1038/nrd4417
    25 sg:pub.10.1038/nrn2851
    26 sg:pub.10.1038/nrneurol.2016.133
    27 sg:pub.10.1038/s41398-020-00978-0
    28 sg:pub.10.1038/s41398-020-0720-2
    29 sg:pub.10.1038/s41598-017-08825-x
    30 sg:pub.10.1186/2040-2392-4-17
    31 sg:pub.10.1186/2040-2392-4-9
    32 sg:pub.10.1186/2040-2392-5-54
    33 sg:pub.10.1186/s11689-017-9195-8
    34 sg:pub.10.1186/s11689-017-9210-0
    35 sg:pub.10.1186/s11689-020-09342-1
    36 sg:pub.10.1186/s13229-015-0025-0
    37 sg:pub.10.1186/s13229-017-0142-z
    38 sg:pub.10.1186/s13229-018-0214-8
    39 sg:pub.10.1186/s13229-018-0231-7
    40 sg:pub.10.1186/s13229-020-00359-w
    41 sg:pub.10.1186/s13229-021-00416-y
    42 sg:pub.10.1186/s13229-021-00432-y
    43 schema:datePublished 2021-09-15
    44 schema:datePublishedReg 2021-09-15
    45 schema:description BackgroundAngelman Syndrome (AS) is a rare neurodevelopmental disorder for which there is currently no cure or effective therapeutic. Since the genetic cause of AS is known to be dysfunctional expression of the maternal allele of ubiquitin protein ligase E3A (UBE3A), several genetic animal models of AS have been developed. Both the Ube3a maternal deletion mouse and rat models of AS reliably demonstrate behavioral phenotypes of relevance to AS and therefore offer suitable in vivo systems in which to test potential therapeutics. One promising candidate treatment is insulin-like growth factor-2 (IGF-2), which has recently been shown to ameliorate behavioral deficits in the mouse model of AS and improve cognitive abilities across model systems.MethodsWe used both the Ube3a maternal deletion mouse and rat models of AS to evaluate the ability of IGF-2 to improve electrophysiological and behavioral outcomes.ResultsAcute systemic administration of IGF-2 had an effect on electrophysiological activity in the brain and on a metric of motor ability; however the effects were not enduring or extensive. Additional metrics of motor behavior, learning, ambulation, and coordination were unaffected and IGF-2 did not improve social communication, seizure threshold, or cognition.LimitationsThe generalizability of these results to humans is difficult to predict and it remains possible that dosing schemes (i.e., chronic or subchronic dosing), routes, and/or post-treatment intervals other than that used herein may show more efficacy.ConclusionsDespite a few observed effects of IGF-2, our results taken together indicate that IGF-2 treatment does not profoundly improve behavioral deficits in mouse or rat models of AS. These findings shed cautionary light on the potential utility of acute systemic IGF-2 administration in the treatment of AS.
    46 schema:genre article
    47 schema:inLanguage en
    48 schema:isAccessibleForFree true
    49 schema:isPartOf N9ef5d12383524a4490b6b8b14aa3ea5d
    50 Ndd3e6aca43f94b948603ce0799822dd3
    51 sg:journal.1043709
    52 schema:keywords AS
    53 Angelman syndrome
    54 E3A
    55 MethodsWe
    56 ability
    57 activity
    58 additional metrics
    59 administration
    60 alleles
    61 ambulation
    62 ameliorate behavioral deficits
    63 animal models
    64 behavior
    65 behavioral deficits
    66 behavioral outcomes
    67 behavioral phenotypes
    68 brain
    69 candidate treatment
    70 cause
    71 cautionary light
    72 cognition
    73 cognitive abilities
    74 communication
    75 coordination
    76 cure
    77 deficits
    78 deletion mice
    79 disorders
    80 dysfunctional expression
    81 effect
    82 effective therapeutics
    83 efficacy
    84 electrophysiological activity
    85 expression
    86 factor 2
    87 findings
    88 generalizability
    89 genetic animal models
    90 genetic cause
    91 growth factor 2
    92 humans
    93 insulin-like growth factor 2
    94 interval
    95 learning
    96 light
    97 maternal allele
    98 metrics
    99 mice
    100 model
    101 model system
    102 more efficacy
    103 motor abilities
    104 motor behavior
    105 mouse model
    106 neurodevelopmental disorders
    107 observed effects
    108 outcomes
    109 phenotype
    110 post-treatment intervals
    111 potential therapeutics
    112 potential utility
    113 promising candidate treatment
    114 rare neurodevelopmental disorder
    115 rat model
    116 relevance
    117 results
    118 route
    119 scheme
    120 seizure threshold
    121 social communication
    122 syndrome
    123 system
    124 systemic administration
    125 therapeutics
    126 threshold
    127 treatment
    128 treatment of AS
    129 ubiquitin protein ligase E3A
    130 utility
    131 vivo system
    132 schema:name Insulin-like growth factor-2 does not improve behavioral deficits in mouse and rat models of Angelman Syndrome
    133 schema:pagination 59
    134 schema:productId Na9aa41b5f8bd411b83a167f6d2dec56a
    135 Nd5338af4366143d88953331c49f54cd9
    136 Nde11c8f1e4c54d25ad3f5029015b5848
    137 schema:sameAs https://app.dimensions.ai/details/publication/pub.1141139387
    138 https://doi.org/10.1186/s13229-021-00467-1
    139 schema:sdDatePublished 2022-05-10T10:30
    140 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    141 schema:sdPublisher Nc8f50e7ca9674b1b8dcc69bc5bd3f998
    142 schema:url https://doi.org/10.1186/s13229-021-00467-1
    143 sgo:license sg:explorer/license/
    144 sgo:sdDataset articles
    145 rdf:type schema:ScholarlyArticle
    146 N116e2863e9ac4affa16f9c0e4ccfd134 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    147 schema:name Insulin-Like Growth Factor II
    148 rdf:type schema:DefinedTerm
    149 N23819f1ff8a244fb8d87af0a26be696b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    150 schema:name Ubiquitin-Protein Ligases
    151 rdf:type schema:DefinedTerm
    152 N3386f17475a94e4e8a98781ec4733dcd rdf:first sg:person.012750173376.16
    153 rdf:rest Nf86ad5b760b7403e99f3a9e8302ac04e
    154 N41dc2d277acb415a982f04371a52999c rdf:first sg:person.01020406761.29
    155 rdf:rest N3386f17475a94e4e8a98781ec4733dcd
    156 N43495c2784c441dfb4d911afc1228f9f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    157 schema:name Brain
    158 rdf:type schema:DefinedTerm
    159 N49d2e3f3e4444d3689754c34e4deca13 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    160 schema:name Rats
    161 rdf:type schema:DefinedTerm
    162 N4b3b2bdda51941d48d218f3b43ba803c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    163 schema:name Disease Models, Animal
    164 rdf:type schema:DefinedTerm
    165 N5130de51710b430aa09e4a60e752d9d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    166 schema:name Mice
    167 rdf:type schema:DefinedTerm
    168 N515ab317165940f9b00ab96a62002b76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    169 schema:name Alleles
    170 rdf:type schema:DefinedTerm
    171 N54d9e11290f34ae5b9bfabaebcb93507 rdf:first sg:person.01314575247.20
    172 rdf:rest rdf:nil
    173 N7f891e4371844b90b64f8822e56e72f1 rdf:first sg:person.012023440035.42
    174 rdf:rest Na9b506367ec64b17acd5661ce8274a63
    175 N9ef5d12383524a4490b6b8b14aa3ea5d schema:issueNumber 1
    176 rdf:type schema:PublicationIssue
    177 Na9aa41b5f8bd411b83a167f6d2dec56a schema:name pubmed_id
    178 schema:value 34526125
    179 rdf:type schema:PropertyValue
    180 Na9b506367ec64b17acd5661ce8274a63 rdf:first sg:person.011662573367.49
    181 rdf:rest N41dc2d277acb415a982f04371a52999c
    182 Nc4af4a7bc7be4bd1bb8e5750253d1a05 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    183 schema:name Animals
    184 rdf:type schema:DefinedTerm
    185 Nc8f50e7ca9674b1b8dcc69bc5bd3f998 schema:name Springer Nature - SN SciGraph project
    186 rdf:type schema:Organization
    187 Nd30ae584d3fd4d81b0c474a5d375ab06 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
    188 schema:name Angelman Syndrome
    189 rdf:type schema:DefinedTerm
    190 Nd5338af4366143d88953331c49f54cd9 schema:name dimensions_id
    191 schema:value pub.1141139387
    192 rdf:type schema:PropertyValue
    193 Ndd3e6aca43f94b948603ce0799822dd3 schema:volumeNumber 12
    194 rdf:type schema:PublicationVolume
    195 Nde11c8f1e4c54d25ad3f5029015b5848 schema:name doi
    196 schema:value 10.1186/s13229-021-00467-1
    197 rdf:type schema:PropertyValue
    198 Nf86ad5b760b7403e99f3a9e8302ac04e rdf:first sg:person.01122163343.90
    199 rdf:rest N54d9e11290f34ae5b9bfabaebcb93507
    200 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    201 schema:name Medical and Health Sciences
    202 rdf:type schema:DefinedTerm
    203 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
    204 schema:name Clinical Sciences
    205 rdf:type schema:DefinedTerm
    206 sg:grant.2699307 http://pending.schema.org/fundedItem sg:pub.10.1186/s13229-021-00467-1
    207 rdf:type schema:MonetaryGrant
    208 sg:grant.6664430 http://pending.schema.org/fundedItem sg:pub.10.1186/s13229-021-00467-1
    209 rdf:type schema:MonetaryGrant
    210 sg:journal.1043709 schema:issn 2040-2392
    211 schema:name Molecular Autism
    212 schema:publisher Springer Nature
    213 rdf:type schema:Periodical
    214 sg:person.01020406761.29 schema:affiliation grid-institutes:grid.25879.31
    215 schema:familyName Born
    216 schema:givenName Heather A.
    217 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01020406761.29
    218 rdf:type schema:Person
    219 sg:person.01122163343.90 schema:affiliation grid-institutes:grid.39382.33
    220 schema:familyName Anderson
    221 schema:givenName Anne E.
    222 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01122163343.90
    223 rdf:type schema:Person
    224 sg:person.011662573367.49 schema:affiliation grid-institutes:grid.27860.3b
    225 schema:familyName Petkova
    226 schema:givenName Stela P.
    227 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011662573367.49
    228 rdf:type schema:Person
    229 sg:person.012023440035.42 schema:affiliation grid-institutes:grid.27860.3b
    230 schema:familyName Berg
    231 schema:givenName Elizabeth L.
    232 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012023440035.42
    233 rdf:type schema:Person
    234 sg:person.012750173376.16 schema:affiliation grid-institutes:grid.27860.3b
    235 schema:familyName Adhikari
    236 schema:givenName Anna
    237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012750173376.16
    238 rdf:type schema:Person
    239 sg:person.01314575247.20 schema:affiliation grid-institutes:grid.27860.3b
    240 schema:familyName Silverman
    241 schema:givenName Jill L.
    242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01314575247.20
    243 rdf:type schema:Person
    244 sg:pub.10.1007/7854_2015_410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003623049
    245 https://doi.org/10.1007/7854_2015_410
    246 rdf:type schema:CreativeWork
    247 sg:pub.10.1038/ejhg.2014.93 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026331838
    248 https://doi.org/10.1038/ejhg.2014.93
    249 rdf:type schema:CreativeWork
    250 sg:pub.10.1038/ng0197-70 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012945311
    251 https://doi.org/10.1038/ng0197-70
    252 rdf:type schema:CreativeWork
    253 sg:pub.10.1038/ng0197-74 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015416100
    254 https://doi.org/10.1038/ng0197-74
    255 rdf:type schema:CreativeWork
    256 sg:pub.10.1038/ng0997-75 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021073892
    257 https://doi.org/10.1038/ng0997-75
    258 rdf:type schema:CreativeWork
    259 sg:pub.10.1038/ng1933 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006673623
    260 https://doi.org/10.1038/ng1933
    261 rdf:type schema:CreativeWork
    262 sg:pub.10.1038/nn.2327 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033476316
    263 https://doi.org/10.1038/nn.2327
    264 rdf:type schema:CreativeWork
    265 sg:pub.10.1038/nn.4592 schema:sameAs https://app.dimensions.ai/details/publication/pub.1086240047
    266 https://doi.org/10.1038/nn.4592
    267 rdf:type schema:CreativeWork
    268 sg:pub.10.1038/npp.2014.69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004023865
    269 https://doi.org/10.1038/npp.2014.69
    270 rdf:type schema:CreativeWork
    271 sg:pub.10.1038/npp.2015.66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004112236
    272 https://doi.org/10.1038/npp.2015.66
    273 rdf:type schema:CreativeWork
    274 sg:pub.10.1038/nprot.2006.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031855645
    275 https://doi.org/10.1038/nprot.2006.205
    276 rdf:type schema:CreativeWork
    277 sg:pub.10.1038/nrd4417 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006881263
    278 https://doi.org/10.1038/nrd4417
    279 rdf:type schema:CreativeWork
    280 sg:pub.10.1038/nrn2851 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027382882
    281 https://doi.org/10.1038/nrn2851
    282 rdf:type schema:CreativeWork
    283 sg:pub.10.1038/nrneurol.2016.133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017529529
    284 https://doi.org/10.1038/nrneurol.2016.133
    285 rdf:type schema:CreativeWork
    286 sg:pub.10.1038/s41398-020-00978-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1130147581
    287 https://doi.org/10.1038/s41398-020-00978-0
    288 rdf:type schema:CreativeWork
    289 sg:pub.10.1038/s41398-020-0720-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1124912055
    290 https://doi.org/10.1038/s41398-020-0720-2
    291 rdf:type schema:CreativeWork
    292 sg:pub.10.1038/s41598-017-08825-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1091148379
    293 https://doi.org/10.1038/s41598-017-08825-x
    294 rdf:type schema:CreativeWork
    295 sg:pub.10.1186/2040-2392-4-17 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030578974
    296 https://doi.org/10.1186/2040-2392-4-17
    297 rdf:type schema:CreativeWork
    298 sg:pub.10.1186/2040-2392-4-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018240013
    299 https://doi.org/10.1186/2040-2392-4-9
    300 rdf:type schema:CreativeWork
    301 sg:pub.10.1186/2040-2392-5-54 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040138850
    302 https://doi.org/10.1186/2040-2392-5-54
    303 rdf:type schema:CreativeWork
    304 sg:pub.10.1186/s11689-017-9195-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085208297
    305 https://doi.org/10.1186/s11689-017-9195-8
    306 rdf:type schema:CreativeWork
    307 sg:pub.10.1186/s11689-017-9210-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090740834
    308 https://doi.org/10.1186/s11689-017-9210-0
    309 rdf:type schema:CreativeWork
    310 sg:pub.10.1186/s11689-020-09342-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1133569238
    311 https://doi.org/10.1186/s11689-020-09342-1
    312 rdf:type schema:CreativeWork
    313 sg:pub.10.1186/s13229-015-0025-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022525805
    314 https://doi.org/10.1186/s13229-015-0025-0
    315 rdf:type schema:CreativeWork
    316 sg:pub.10.1186/s13229-017-0142-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1086046227
    317 https://doi.org/10.1186/s13229-017-0142-z
    318 rdf:type schema:CreativeWork
    319 sg:pub.10.1186/s13229-018-0214-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103669008
    320 https://doi.org/10.1186/s13229-018-0214-8
    321 rdf:type schema:CreativeWork
    322 sg:pub.10.1186/s13229-018-0231-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106989860
    323 https://doi.org/10.1186/s13229-018-0231-7
    324 rdf:type schema:CreativeWork
    325 sg:pub.10.1186/s13229-020-00359-w schema:sameAs https://app.dimensions.ai/details/publication/pub.1128794428
    326 https://doi.org/10.1186/s13229-020-00359-w
    327 rdf:type schema:CreativeWork
    328 sg:pub.10.1186/s13229-021-00416-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1135183861
    329 https://doi.org/10.1186/s13229-021-00416-y
    330 rdf:type schema:CreativeWork
    331 sg:pub.10.1186/s13229-021-00432-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1136612444
    332 https://doi.org/10.1186/s13229-021-00432-y
    333 rdf:type schema:CreativeWork
    334 grid-institutes:grid.25879.31 schema:alternateName Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    335 schema:name Department of Pediatrics and Neurology, Baylor College of Medicine, Houston, TX, USA
    336 Gene Therapy Program, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
    337 rdf:type schema:Organization
    338 grid-institutes:grid.27860.3b schema:alternateName MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA
    339 schema:name MIND Institute and Department of Psychiatry and Behavioral Sciences, University of California Davis School of Medicine, Sacramento, CA, USA
    340 rdf:type schema:Organization
    341 grid-institutes:grid.39382.33 schema:alternateName Department of Pediatrics and Neurology, Baylor College of Medicine, Houston, TX, USA
    342 schema:name Department of Pediatrics and Neurology, Baylor College of Medicine, Houston, TX, USA
    343 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...